Company: ANTX
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0000950170-25-107301
Chunk: 5

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 2
Chunk 5
---
 the University of Georgia Research Foundation to advance the development of AN2-502998, originally discovered by researchers at Anacor, in close collaboration with the University of Georgia. AN2-502998 is the only compound of which we are aware to have demonstrated curative activity in preclinical studies across multiple species, including in non-human primates with long-term, naturally acquired chronic infections of diverse T. cruzi genetic types. We anticipate completion of dosing in the Phase 1 study in the second half of 2025, and anticipate initiation of a Phase 2 proof-of-concept study in 2026.  In July 2025, we announced a collaboration with the non–profit medical research organization Drugs for Neglected Diseases initiative (“DNDi”) to advance clinical development of AN2-502998. Through the collaboration, DNDi will share its extensive clinical trial network and expertise in Chagas disease to rapidly advance the clinical development of AN2-502998.

We are pursuing a number of oncology targets where we believe boron chemistry offers a competitive advantage in terms of binding-site differentiation, pharmacodynamics, drug-like properties and IP, including initially ENPP1 and PI3Kα. The unique binding modes of boron-containing compounds enable the discovery of inhibitors with high ligand efficiency against targets considered undruggable or difficult to access with traditional chemistry approaches. Boron chemistry has produced first-in-class molecules against a number of targets including CPSF3 (AN2-502998 and acoziborole) and LeuRS (epetraborole, ganfeborole and tavaborole). The Company has discovered preclinical compounds with profiles that are sub-nanomolar, highly selective and have excellent oral pharmacokinetics. We anticipate advancing the first oncology compound into development later this year with potential clinical proof of concept within the Company’s current cash runway. We expect to advance our second oncology compound into development in the first half of 2026.